DKK1 Gene Editing

CBpromise   

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER

DKK1 Gene Editing    

DKK1 (dickkopf-related protein 1) is a member of the dickkopf family. This secreted protein family shares a similar conserved cysteine domain and inhibits the Wnt/β-catenin pathway by causing proteasome β-catenin degradation, inducing apoptosis and preventing cell proliferation. DKK1 is a discovered secretory glycoprotein that induces the head formation and is an endogenous inhibitor of the canonical Wnt/β-catenin signaling pathway. It has been found to be involved in many pathophysiological processes in the body. Abnormal expression of DKK1 not only alters the expression of related proteins and genes in the canonical Wnt/β-catenin signaling pathway but also alters the expression of related proteins and genes in other signaling pathways.

DKK1 regulation of signaling pathways Figure 1: DKK1 regulation of signaling pathways (Michael H Kagey. 2017).

Numerous studies have shown that it plays an important role in embryonic development, nerve regeneration, and synapse formation. Therefore, its role in neuropsychiatric disorders, such as neurodevelopmental disorders, cognitive disorders, and mood disorders, has attracted increasing attention. At present, the role of DKK1 in Alzheimer's disease (AD) is one of the research hotspots.

Elevated levels of DKK1 in plasma and peripheral blood in patients with multiple myeloma are associated with osteolytic lesions. Due to the role of DKK1 in inflammation-induced bone loss, DKK1 is currently being studied as a target for medical and dental treatment strategies.

In addition, recent studies have shown that DKK1 may be an ideal target for cancer immunotherapy. Interestingly, the DKK1-CKAP4-PI3K/AKT signaling pathway also plays a role in the proliferation of pancreatic cancer cells. It may be useful to further study the mechanism of DKK1 and use it alone as a biomarker or in combination with other biomarkers.

DKK1 Gene Editing Service

CRISPR/Cas9 PlatformCB, a global leading biotechnological company specializing in gene editing, is dedicated to offering comprehensive CRISPR/Cas9 gene editing services and products to a wide range of genomics researchers. Based on our platform, we can help you effectively control target genes deleted, inserted or point mutated in cells or animals via CRISPR/Cas9 technology.

  • DKK1 Gene Editing Cell Line Generation

With deep gene editing knowledge and extensive experience in experimental operation and data processing, we have successfully implemented DKK1 CRISPR/Cas9 gene edited in both easy-to-transfect cell lines and hard-to-transfect cells. To support your projects, we will offer you full-length custom DKK1 gene editing service from strategy design to final stable cells. Our DKK1 gene editing cell line generation services include:

➢ gRNA design and synthesis
➢ Transfect the cell lines you're interested
➢ Select the high expression cells and sort monoclonal cell
➢ Validate the knockout/knockin/point mutation of DKK1 by PCR and sequencing
➢ Produce cryogenic preserved vials of stable cells and a final report

Typically, we develop CRISPR-mediated gene editing cell lines including HEK239T, Hela, HepG2, U87, but we can use other cell lines according to your requirements.

  • Alternative cell lines

➢ Blood Lineage Cells (RAW264.7, HMC1.2, K562, U937 etc.)
➢ Cancer Cell Lines (HEK293, HEK293T, Hela, MCF7, Neuro2a, HepG2, U87 etc.)
➢ Stem Cells (iPSC)
➢ Other Cell Lines (NIH3T3, MCF10, HEME, SW10 etc.)

  • DKK1 Gene Editing Animal Model Generation

CRISPR/Cas9 PlatformCB also has extensive experience in incorporating CRISPR/Cas9 technology into animal models, which have been fully recognized by our clients. Tell us your needs, we provide a one-stop-shop DKK1 CRISPR/Cas9 gene editing animal service and guarantee at least 2 founders or 3 F1 animals with shorter turnaround time and lower price. Our DKK1 gene editing animal model generation services include:

➢ DKK1 gene conventional knockout animals
➢ DKK1 gene conditional knockout animals
➢ DKK1 point mutation animals
➢ DKK1 knockin animals

Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.

CRISPR/Cas9 PlatformCB is devoted to providing the best gene editing services and products for academic research, biotech research and pharmaceutical drug discovery with excellent quality management and quality assurance capacity. To accelerate the achievement of your research goals, our gene editing expert team provides you with custom CRISPR/Cas9 services for any specific gene to help you solve problems encountered during your research. If you have any question, please feel free to contact us.

Related Products at CRISPR/Cas9 PlatformCB

CATALOG NO. PRODUCT NAME INQUIRY
CLKO-0059DKK1 KO Cell Lysate-HeLaInquiry
CSC-RT0554Human DKK1 Knockout Cell Line-HeLaInquiry
CCKM0148B6J-Dkk1em1CdInquiry

References

  1. Chao Ren. et al. The role of DKK1 in Alzheimer's disease: A potential intervention point of brain damage prevention? Pharmacological Research. 2019; 144:331–335.
  2. Eseosaserea Igbinigie. et al. Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma. Clinica Chimica Acta. 2019; 488:226–234.
  3. Atsushi Niida. et al. DKK1, a negative regulator of Wnt signaling, is a target of the β-catenin/TCF pathway. Oncogene. 2004; 23: 8520–8526.
  4. Erming Tian. et al. The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma. N Engl J Med. 2003; 349:2483-2494.
  5. Mohammad Samiei. et al. The role of sclerostin and dickkopf-1 in oral tissues – A review from the perspective of the dental disciplines. Version 1. F1000Res. 2019; 8:128.
  6. Michael H Kagey & Xi He. Rationale for targeting the Wnt signalling modulator Dickkopf‐1 for oncology. Br J Pharmacol. 2017; 174(24): 637–4650.
For research use only. Not intended for any clinical use.

Inquiry

Please input "biogene" as verification code.